Starling Oncology, Inc. Payments of Stock Issuance Costs
Starling Oncology, Inc. (STLN) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2022-03-11
- Starling Oncology, Inc. payments of stock issuance costs for the quarter ending 2020-12-31 was -$3.78M.
- Starling Oncology, Inc. payments of stock issuance costs for the quarter ending 2020-09-30 was $35.12K.
- Starling Oncology, Inc. payments of stock issuance costs for the quarter ending 2020-06-30 was $1.55K.
- Starling Oncology, Inc. payments of stock issuance costs for the quarter ending 2020-03-31 was $4.09M.
- Starling Oncology, Inc. payments of stock issuance costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Starling Oncology, Inc. payments of stock issuance costs for fiscal 2020 was $343.00K.
| Period end | Payments of Stock Issuance Costs 2 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-11 | |||||
| 2020-12-31 | -$3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$3.75M derived: sum of 2 quarters · filed 2022-03-11 | -$3.75M derived: sum of 3 quarters · filed 2022-03-11 | $343.00K 10-K · filed 2022-03-11 | $4.13M 10-K · filed 2021-03-30 | |
| 2020-09-30 | $35.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $36.67K derived: sum of 2 quarters · filed 2021-08-16 | $4.13M 10-Q · filed 2020-11-13 | |||
| 2020-06-30 | $1.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $4.09M 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | $4.09M 10-Q · filed 2021-05-28 | |||||
| 2019-12-31 | $0.00 10-K/A · filed 2021-12-14 |